We are live on ! Find out more
VTGN icon

VistaGen Therapeutics
VTGN

74 hedge funds and large institutions have $227M invested in VistaGen Therapeutics in 2021 Q1 according to their latest regulatory filings, with 32 funds opening new positions, 28 increasing their positions, 5 reducing their positions, and 10 closing their positions.

New
Increased
Maintained
Reduced
Closed

460% more repeat investments, than reductions

Existing positions increased: 28 | Existing positions reduced: 5

220% more first-time investments, than exits

New positions opened: 32 | Existing positions closed: 10

100% more funds holding in top 10

Funds holding in top 10: 1 → 2 (+1)

78% more capital invested

Capital invested by funds: $127M → $227M (+$99.2M)

42% more funds holding

Funds holding: 52 → 74 (+22)

0.83% more ownership

Funds ownership: 1.63% → 2.46% (+0.83%)

Holders
74
Holders Change
+22
Holders Change %
+42.31%
% of All Funds
1.3%
Holding in Top 10
2
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+100%
% of All Funds
0.04%
New
32
Increased
28
Reduced
5
Closed
10
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
NMC
NEA Management Company
Maryland
+$15.4M
2
VA
VR Adviser
New York
+$15.4M
3
ACP
Acuta Capital Partners
California
+$10.7M
4
Franklin Resources
Franklin Resources
California
+$10.3M
5
MWNA
Marshall Wace North America
New York
+$6.29M

Top Sellers

Rank Fund Capital Flow
1
ACM
Asymmetry Capital Management
California
-$4.34M
2
IC
Ikarian Capital
Texas
-$3.56M
3
PVI
Pura Vida Investments
New York
-$2.83M
4
GPCM
Granite Point Capital Management
Massachusetts
-$1.88M
5
Renaissance Technologies
Renaissance Technologies
New York
-$1.62M
Name Holding Trade Value Shares
Change 		Change in
Stake
BFM
26
Boothbay Fund Management
New York
$641K -$371K -5,557 -36%
SSA
27
Schonfeld Strategic Advisors
New York
$574K +$427K +6,390 +245%
Northern Trust
28
Northern Trust
Illinois
$560K +$370K +5,549 +173%
Susquehanna International Group
29
Susquehanna International Group
Pennsylvania
$538K +$562K +8,416 New
Goldman Sachs
30
Goldman Sachs
New York
$486K +$321K +4,804 +171%
Osaic Holdings
31
Osaic Holdings
Arizona
$365K – – –
HF
32
HRT Financial
New York
$356K +$373K +5,582 New
DADC
33
D.A. Davidson & Co
Montana
$284K -$8.88K -133 -3%
QSS
34
Quantitative Systematic Strategies
Florida
$280K +$136K +2,034 +87%
HighTower Advisors
35
HighTower Advisors
Illinois
$269K +$281K +4,203 New
Capstone Investment Advisors
36
Capstone Investment Advisors
New York
$267K +$119K +1,786 +75%
EWA
37
Exencial Wealth Advisors
Oklahoma
$264K +$277K +4,143 New
Citadel Advisors
38
Citadel Advisors
Florida
$230K +$241K +3,607 New
CSS
39
Cubist Systematic Strategies
Connecticut
$209K +$175K +2,620 +399%
LP
40
LMR Partners
United Kingdom
$181K +$189K +2,826 New
OFA
41
Oak Family Advisors
Illinois
$149K -$31K -465 -17%
MHS
42
M Holdings Securities
Oregon
$136K +$142K +2,133 New
Bank of New York Mellon
43
Bank of New York Mellon
New York
$134K +$11.4K +171 +9%
VF
44
Virtu Financial
New York
$132K +$138K +2,071 New
Citigroup
45
Citigroup
New York
$111K +$116K +1,742 New
Charles Schwab
46
Charles Schwab
California
$107K +$111K +1,659 New
Parallax Volatility Advisers
47
Parallax Volatility Advisers
California
$95K – – –
TRCT
48
Tower Research Capital (TRC)
New York
$95K +$99.2K +1,486 New
LPL Financial
49
LPL Financial
California
$85K +$33.4K +500 +60%
T. Rowe Price Associates
50
T. Rowe Price Associates
Maryland
$84K +$87.9K +1,317 New
1
2
3 4

VTGN Hedge Fund Activity: Q1 2021 in Review

74 of the 5,695 institutional investors tracked by Wall St. Rank reported a position in VistaGen Therapeutics (VTGN) for Q1 2021, worth a combined $227M — up 78% from $127M a quarter earlier.

Buyers outnumbered sellers: 32 funds opened new VTGN positions and 10 closed out — a net gain of 22 holders — while 28 added to existing stakes and 5 trimmed.

The largest buyer was NEA Management Company, adding an estimated $15.4M. The largest seller was Asymmetry Capital Management, exiting entirely with an estimated $4.34M sold.

  • 74 institutional investors held VistaGen Therapeutics (VTGN) as of Q1 2021, up from 52 in Q4 2020.
  • Funds reported $227M of VistaGen Therapeutics stock for Q1 2021, up 78% quarter-over-quarter.
  • 32 funds opened new VistaGen Therapeutics positions in Q1 2021 and 10 closed out, a net change of +22 holders.
  • The largest VistaGen Therapeutics buyer in Q1 2021 was NEA Management Company, an estimated $15.4M added.
  • The largest VistaGen Therapeutics seller in Q1 2021 was Asymmetry Capital Management, an estimated $4.34M sold.

Based on aggregated 13F filings for Q1 2021.